Top

Published in:

Open Access 01-06-2018 | Original Research

Intraoperative radiation therapy as part of planned monotherapy for early-stage breast cancer

Authors: Varun K. Chowdhry, Julie A. Bushey, Rebecca M. Kwait, Saveli Goldberg, Jeannine Ritchie, Yong-Li Ji, Roderick McKee, Diane Palladino, Gary M. Proulx

Published in: Journal of Radiation Oncology | Issue 2/2018

Abstract

Introduction

Adjuvant whole breast radiation therapy has developed into the standard of care for patients following a lumpectomy for early-stage breast cancer. However, there is recent interest in intraoperative radiation therapy (IORT) to minimize toxicity while still improving local control beyond surgical resection and anti-estrogen therapy alone.

Materials and methods

All patients were evaluated pre-operatively in a multidisciplinary clinic setting at a community hospital for suitability for breast conservation therapy. A total of 109 patients were reviewed receiving 110 IORT treatments. Patients were followed with clinical breast examinations and mammography as clinically indicated.

Results

At a median follow-up of 29.9 months, 2/110 (1.8%) patients experienced a local failure. One patient (0.9%) experienced a regional failure. Local control, disease-free survival and overall survival at 3 years were 98.9% (95%CI 92.2–99.8), 97.2% (95%CI 88.9–99.3), and 96.0% (95%CI 84.9–99.0), respectively. Five-year local control, disease-free survival, and overall survival rates were 96.3% (95%CI 84.7–99.2), 94.6% (95%CI 83.2–98.3), and 92.5% (95%CI 80.4–97.3), respectively. Patient self-reported cosmetic outcome was available for 51 patients, with all patients reporting being either very pleased, pleased, or satisfied with their cosmetic outcome, and no patients reported being dissatisfied or worse.

Conclusions

The results of our series suggest the feasibility of utilizing IORT in a community-based cancer center with a high degree of local control, and patient satisfaction with regard to cosmesis. While the results of this series suggest that IORT may be a promising modality, longer follow-up is warranted to better understand exactly which clinicopathological features can predict long-term locoregional disease control.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. Ann Surg Oncol. 2015 Apr;22(4):1095–101. https://doi.org/10.1245/s10434-014-4093-8 CrossRef

Goyal S, Chandwani S, Haffty BG, Demissie K (2015) Effect of travel distance and time to radiotherapy on likelihood of receiving mastectomy. Ann Surg Oncol 22(4):1095–1101. https://doi.org/10.1245/s10434-014-4093-8 CrossRefPubMed

Acharya S, Hsieh S, Michalski JM, Shinohara ET, Perkins SM (2016) Distance to radiation facility and treatment choice in early-stage breast cancer. Int J Radiat Oncol Biol Phys 94(4):691–699. https://doi.org/10.1016/j.ijrobp.2015.12.020 CrossRefPubMed

Willett CG, Czito BG, Tyler DS (2007) Intraoperative radiation therapy. J Clin Oncol 25(8):971–977. https://doi.org/10.1200/JCO.2006.10.0255 CrossRefPubMed

Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M, TARGIT trialists’ group (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917):603–613. https://doi.org/10.1016/S0140-6736(13)61950-9 CrossRefPubMed

Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Gutierrez Miguelez C, Slampa P, Allgäuer M, Lössl K, Polat B, Kovács G, Fischedick AR, Wendt TG, Fietkau R, Hindemith M, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Pötter R, Gall C, Malzer M, Uter W, Polgár C, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO) (2016) 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 387(10015):229–238. https://doi.org/10.1016/S0140-6736(15)00471-7 CrossRefPubMed

Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM, IMPORT Trialists (2017) Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 390(10099):1048–1060. https://doi.org/10.1016/S0140-6736(17)31145-5 CrossRefPubMedPubMedCentral

Silverstein MJ, Fastner G, Maluta S, Reitsamer R, Goer DA, Vicini F, Wazer D (2014) Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 1—ELIOT. Ann Surg Oncol 21(12):3787–3792. https://doi.org/10.1245/s10434-014-3998-6 CrossRefPubMedPubMedCentral

Krug D, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Piroth MD, Sautter-Bihl ML, Sedlmayer F, Souchon R, Wenz F, Sauer R (2017) Breast cancer expert panel of the German Society of Radiation Oncology (DEGRO). Current controversies in radiotherapy for breast cancer. Radiat Oncol 12(1):25. https://doi.org/10.1186/s13014-017-0766-3 CrossRefPubMedPubMedCentral

10.

Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M (2010) Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 376(9735):91–102. https://doi.org/10.1016/S0140-6736(10)60837-9 CrossRefPubMed

11.

Dickler A, Ivanov O, Francescatti D (2009) Intraoperative radiation therapy in the treatment of early-stage breast cancer utilizing xoft axxent electronic brachytherapy. World J Surg Oncol 7(1):24. https://doi.org/10.1186/1477-7819-7-24 CrossRefPubMedPubMedCentral

12.

Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, Luini A, Veronesi P, Galimberti V, Zurrida S, Leonardi MC, Lazzari R, Cattani F, Gentilini O, Intra M, Caldarella P, Ballardini B (2013) Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 14(13):1269–1277. https://doi.org/10.1016/S1470-2045(13)70497-2 CrossRefPubMed

13.

Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, White J, Harris JR (2017) Accelerated partial breast irradiation: executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol 7(2):73–79. https://doi.org/10.1016/j.prro.2016.09.007 CrossRefPubMed

14.

Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System. US National Library of Medicine. Clinical Trials.gov. Online. Internet. Accessed 11 October 2017. https://clinicaltrials.gov/ct2/show/NCT01644669

15.

Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM (2013) Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol 20(9):2873–2880. https://doi.org/10.1245/s10434-013-2997-3 CrossRefPubMed

16.

Shah C, Badiyan S, Khwaja S, Shah H, Chitalia A, Nanavati A, Kundu N, Vaka V, Lanni TB, Vicini FA (2014) Evaluating radiotherapy options in breast cancer: does intraoperative radiotherapy represent the most cost-efficacious option? Clin Breast Cancer 14(2):141–146. https://doi.org/10.1016/j.clbc.2013.10.005 CrossRefPubMed

17.

Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31(19):2382–2387. https://doi.org/10.1200/JCO.2012.45.2615 CrossRefPubMedPubMedCentral

18.

Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 16(3):266–273. https://doi.org/10.1016/S1470-2045(14)71221-5 CrossRefPubMed

19.

Sedlmayer F, Reitsamer R, Wenz F, Sperk E, Fussl C, Kaiser J, Ziegler I, Zehentmayr F, Deutschmann H, Kopp P, Fastner G (2017) Intraoperative radiotherapy (IORT) as boost in breast cancer. Radiat Oncol 12(1):23. https://doi.org/10.1186/s13014-016-0749-9 CrossRefPubMedPubMedCentral

20.

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer. US National Library of Medicine. Clinical Trials.gov. Online. Internet. Accessed 3 October 2017. https://clinicaltrials.gov/ct2/show/NCT00103181

Title: Intraoperative radiation therapy as part of planned monotherapy for early-stage breast cancer
Authors: Varun K. Chowdhry
Julie A. Bushey
Rebecca M. Kwait
Saveli Goldberg
Jeannine Ritchie
Yong-Li Ji
Roderick McKee
Diane Palladino
Gary M. Proulx
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Radiation Oncology / Issue 2/2018
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-017-0338-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Comparison between CT- and MRI-derived head and neck cancer target volumes using an integrated MRI-tri-60Co teletherapy device

Image-guided adaptive radiotherapy improves acute toxicity during intensity-modulated radiation therapy for head and neck cancer

The use of stereotactic radiosurgery for benign spinal tumors: single institution experience

THE PROCEEDINGS OF THE RADIATION ONCOLOGY SUMMIT: ACRO 2018

An economic analysis of Radiation Therapy Oncology Group 94-10: cost-efficacy of concurrent vs. sequential chemoradiotherapy

Radical treatment of muscle-invasive bladder cancer—are options equal?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer